$0.27
6.13% day before yesterday
Nasdaq, Dec 27, 10:13 pm CET
ISIN
US45674E1091
Symbol
INAB
Sector
Industry

IN8bio Inc Stock price

$0.27
-0.03 8.85% 1M
-0.63 69.98% 6M
-1.11 80.43% YTD
-1.15 80.99% 1Y
-5.30 95.15% 3Y
-9.73 97.30% 5Y
-9.73 97.30% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.02 6.13%
ISIN
US45674E1091
Symbol
INAB
Sector
Industry

Key metrics

Market capitalization $19.57m
Enterprise Value $21.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.47
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-30.97m
Free Cash Flow (TTM) Free Cash Flow $-25.20m
Cash position $4.00m
EPS (TTM) EPS $-0.75
P/E forward negative
Short interest 1.83%
Show more

Is IN8bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

IN8bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a IN8bio Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a IN8bio Inc forecast:

Buy
80%
Hold
20%

Financial data from IN8bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.58 2.58
16% 16%
-
-2.58 -2.58
16% 16%
-
- Selling and Administrative Expenses 7.92 7.92
20% 20%
-
- Research and Development Expense 18 18
10% 10%
-
-28 -28
0% 0%
-
- Depreciation and Amortization 2.58 2.58
16% 16%
-
EBIT (Operating Income) EBIT -31 -31
1% 1%
-
Net Profit -32 -32
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about IN8bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IN8bio Inc Stock News

Neutral
GlobeNewsWire
19 days ago
IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
Neutral
GlobeNewsWire
about 2 months ago
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers a...
Neutral
GlobeNewsWire
4 months ago
Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30, 2024. Suspending enrollment of Phase 2 clinical trial of INB-400 in newly diagnosed GBM; will continue to monitor patients...
More IN8bio Inc News

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Head office United States
CEO William Ho
Employees 31
Founded 2016
Website www.in8bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today